Exact sciences corporation stock.
15-May-2017 ... One week after hitting an all-time high, Exact Sciences Corp. stock slipped as much as 8 percent in early trading Monday after a well-known ...
Exact Sciences Corp. (EXAS) will release its next earnings report on Feb 20, 2024. In the last quarter Exact Sciences Corp. reported -$0.471 EPS in relation to $0 expected by the market. ... Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including ...MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's 0.3750% Convertible Senior Notes due 2027 (the "Existing 2027 ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...MADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, ... Represents severance, accelerated stock-based compensation expense, ...
Nov 30, 2023Oct 9, 2023 · Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ... Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful treatment. Our Tests
A high-level overview of Exact Sciences Corporation (EXAS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment …
MADISON, Wis., August 1, 2023 -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $622.1 million for the second quarter ended June 30, 2023, compared to $521.6 million for the same period of 2022.Get EXACT Sciences Corporation (EXAS) share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial ...The number of shares outstanding of the Registrant’s $0.01 par value Common Stock as of February 20, 2023 was178,217,142. ... EXACT SCIENCES CORPORATION ANNUAL REPORT ON FORM 10‑K YEAR ENDED DECEMBER 31, 2022 TABLE OF CONTENTS Page No. Part I Item 1. Business 4 Item 1A. Risk Factors 19Sep 9, 2023 · Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ...
Imperialism exists today, but not in the exact form practiced during the Roman Empire or the British Empire. Capitalism is a major driver of modern imperialism as corporations, such as banks and oil companies, expand globally to generate mo...
Jul 10, 2023 · Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after ...
May 9, 2023 · MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022. About Exact Sciences Corp. ... 2022 and 2021. Stock-based compensation including the incremental fair value of assumed stock awards and accelerated vesting from post-acquisition qualified termination events was zero for the three and six months ended June 30, 2022, compared to $2.4 million and $102.8 million for the three and six months …From hereditary cancer testing and earlier cancer screenings to treatment guidance and therapy selection, we aim to offer a comprehensive suite of tests that ...Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer ...Exact Sciences Corp (NASDAQ:EXAS) reported Q2 revenue of $622 million, an increase of 19%, and $617 million of core revenue, an increase of 24%, beating the consensus of $599.03 million.
Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ...The Exact Sciences Corp NASDAQ: EXAS stock price reached the ceiling this week, with shares gaining a sizable 16.38% over the past five days. Most of that value climb came yesterday, with the molecular diagnostic company's stock gaining 24.65% at the end of the trading session. Putting this figure into perspective is that the S&P 500 finished ...At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard ® and Oncotype ® tests, Exact Sciences is investing in its pipeline to develop innovative …MADISON - Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware. The lawsuit seeks damages and a court order to stop Geneoscopy from making, using, selling, or …Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ...
View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ.Nov 1, 2023 · Third-quarter 2023 financial results. For the three-month period ended September 30, 2023, as compared to the same period of 2022 (where applicable): • Total revenue was $628.3 million, an increase of 20 percent. • Core revenue was $624.8 million, an increase of 23 percent. • Screening revenue was $472.0 million, an increase of 31 percent.
Exact Sciences' stock was down by 11.2% on sky-high volume as of 3:30 p.m. ET Wednesday afternoon. Although 2023 Q2 revenue jumped 19% year over year to $622 million, Wall Street apparently wanted ...The EXACT Sciences Corporation stock price gained 1.49% on the last trading day (Monday, 20th Nov 2023), rising from $66.30 to $67.29. During the last trading day the stock fluctuated 4.45% from a day low at $66.31 to a day high of $69.26. The price has been going up and down for this period, and there has been a 3.21% gain for the last …Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 16.9% so far this month. During the month of September, Exact Sciences Corp’s stock price has reached a high of $85.71 and a low of $69.26. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $29.27. Year to date, Exact ...Shares Held % O/S Share Change Filing Date; The Vanguard Group, Inc. 17,175: 9.52: 164: 06/30/2023: JPMorgan Investment Management, Inc. 12,307: 6.82: 878: 06/30/2023Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 7.65% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to date, Exact ...Zacks Equity Research. Exact Sciences (EXAS) closed the most recent trading day at $66.08, moving -1.42% from the previous trading session. This change was narrower than the S&P 500's daily loss ...Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ...But EXAS stock toppled 4.3% on Wednesday after the company announced the Blue-C results. The tumble is likely related to the new product's minimal improvement in finding precancerous polyps. Those ...07-Oct-2020 ... What is Exact Sciences Corporation stock price? On 2023-12-01, Exact Sciences Corporation (EXAS-Q) stock closed at a price of $67.03.
On July 24, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $93.84 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 0.09%, and its shares gained 105.65% ...
Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Our pipeline team is responsible for advancing our future tests and developing life-changing cancer diagnostics to help patients throughout the course of their diagnosis and treatment.On November 30, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $64.00 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38. ...Exact Sciences (EXAS) stock is on the rise Friday following news that Guardant Health's (GH) clinical trial didn't go as well as expected. GH is pushing EXAS higher today Source: Shutterstock Exact Sciences (NASDAQ:EXAS) stock is on the ris...MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022.Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more.intraday 1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Wednesday 11/29/2023 the closing price of the EXACT …Shares of Exact Sciences (NASDAQ:EXAS) were soaring 9.8% higher as of 3:38 p.m. EDT on Thursday. The company announced on Wednesday that new data for its ...The latest EXACT Sciences stock prices, stock quotes, news, and EXAS history to help you invest and trade smarter. ... EXACT Sciences Corp. is a cancer screening and diagnostics company.Nov 1, 2023 · Third-quarter 2023 financial results. For the three-month period ended September 30, 2023, as compared to the same period of 2022 (where applicable): • Total revenue was $628.3 million, an increase of 20 percent. • Core revenue was $624.8 million, an increase of 23 percent. • Screening revenue was $472.0 million, an increase of 31 percent. Nov 22, 2023 · Buy candidate since Nov 17, 2023 Loss -1.39% PDF. The EXACT Sciences Corporation stock price gained 0.368% on the last trading day (Wednesday, 22nd Nov 2023), rising from $65.14 to $65.38. During the last trading day the stock fluctuated 3.02% from a day low at $64.84 to a day high of $66.80. The price has been going up and down for this period ... 09-Oct-2023 ... MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, ...Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful treatment. Our Tests
Exact Sciences Announces Fourth Quarter 2022 Results Reports record revenue, expects revenue of $2,265-2,315 million and positive adjusted EBITDA for full year 2023 02-21 - 1 view. CONSULTING AGREEMENT 02-21. EXACT SCIENCES CORPORATION EQUITY AWARD DEATH, DISABILITY AND RETIREMENT POLICY …Exact Sciences (EXAS) stock is on the rise Friday following news that Guardant Health's (GH) clinical trial didn't go as well as expected. GH is pushing EXAS higher today Source: Shutterstock Exact Sciences (NASDAQ:EXAS) stock is on the ris...Exact Sciences has an Altman Z-Score of 1.76 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Exact Sciences Corporation (EXAS) stock, including valuation metrics, financial numbers, share information and more.Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ... Instagram:https://instagram. dental and vision insurance plans in georgiablackstone and blackrockdividend etfs that pay monthlya i t Nov 14, 2023 · Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 3.04% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to date, Exact ... Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 16.9% so far this month. During the month of September, Exact Sciences Corp’s stock price has reached a high of $85.71 and a low of $69.26. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $29.27. Year to date, Exact ... alternatives to acornsvangaurd bond fund Nov 14, 2023 · Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 3.04% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to date, Exact ... MADISON, Wis., April 26, 2022 -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $486.6 million for the first quarter ended March 31, 2022, compared to $402.1 million for the same period of 2021. best reit dividends 26-Apr-2022 ... MADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that ...Oncotype DX ® Test Recognized as the 'Preferred' and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer. Update based on first results from the independent RxPONDER study presented at the 2020 San Antonio Breast Cancer Symposium 1. Madison, Wis., March 31, 2021 - Exact Sciences today …Transcript : Exact Sciences Corporation, Q3 2023 Earnings Call, Nov 01, 2023. Nov. 01. CI. Earnings Flash (EXAS) EXACT SCIENCES CORPORATION Reports Q3 Revenue $628.3M, vs. Street Est of $617.2M. Nov. 01. MT. Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023. Nov. 01.